Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Serum Sestrin2 and PlGF levels in pregnant women with pre-eclampsia and their correlations with the severity of the disease: A case-control study

Lijun Li, Zhen Sun, Shasha Liu, Hongyan Cui

Obstetrics Department, Tianjin Central Hospital of Gynecology Obstetrics, 156 Nankai 3rd Road, Nankai, Tianjin, 300100, China;

For correspondence:- Hongyan Cui Email: yhf56685@126.com

Accepted: 17 December 2020 Published: 31 January 2021

Citation: Li L, Sun Z, Liu S, Cui H. Serum Sestrin2 and PlGF levels in pregnant women with pre-eclampsia and their correlations with the severity of the disease: A case-control study. Trop J Pharm Res 2021; 20(1):53-60 doi: 10.4314/tjpr.v20i1.9

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: Sestrin2, a metabolic regulator with antioxidant activity, might have some certain predictability for the occurrence and severity of pre-eclampsia (PE). The purpose of this work was to explore the levels of serum Sestrin2 and PlGF in pregnant women with PE and their correlation with the severity index of the disease.

Methods:This was a retrospective case-control study of pregnant women with PE who planned to give birth in our hospital from 05/2017 to 05/2019. Pearson correlation was used to analyze Sestrin2 and PlGF levels with PE severity. Receiver operating characteristic (ROC) curves were used to evaluate the predictive value of Sestrin2 and PlGF for PE.

Results: There were 52 women in the control group, 46 in the mild PE group, and 36 in the severe PE group. As the severity of PE increased, the median levels of Sestrin2 increased (8.1, 9.8, and 11.8 ng/ml), and the levels of PlGF decreased (156, 117, and 67 pg/ml) in the three groups of women (all P<0.05).The levels of Sestrin2 and PlGF were strongly correlated with mean arterial pressure, proteinuria, newborn birth weight and gestational weeks at delivery (all P<0.001). Sestrin2 and PlGF had high efficiency of diagnosing PE (cut-off: 8.90 ng/ml, Area Under Curve [AUC]=0.979; cut-off: 122.50 pg/ml, AUC=0.963). Additionally, Sestrin2 and PlGF showed high value of severity prediction (cut-off: 11.15 ng/ml, AUC=0.857; cut-off: 68.50 pg/ml, AUC=0.837).

Conclusion: Sestrin2 and PlGF are correlated with the severity of PE. Both Sestrin2 and PlGF had high value for PE diagnosis and severity prediction.

Keywords: Pre-eclampsia; Sestrin2; placental growth factor; oxidative stress; severity